Clinical Trial Update: Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Completed Phase 2 trial evaluating SAR240550 (BSI-201) in combination with gemcitabine and carboplatin for metastatic triple-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Gemzar (gemcitabine)
• Iniparib (BSI-201) (iniparib)

Snippet

Sponsor: Sanofi | Conditions: Breast Cancer, Metastatic | Phase 2 | Status: COMPLETED